Analytical Data
-
Gene name
CD8 alpha
- Application
-
Alternative Names
p32; CD8-A; Leu2; MAL; T-cell surface glycoprotein CD8 alpha chain; T-lymphocyte differentiation antigen T8/Leu-2
-
Species
Human
-
Source
HEK293
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P01732
-
Expression Region
Ser22~Val235
-
Molecular Weight
30kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD8 alpha (CD8α) is an essential co-receptor expressed on cytotoxic T lymphocytes, playing a crucial role in the immune response by enhancing the recognition of antigen-presenting cells and facilitating the activation of T cells. The importance of CD8α in immune surveillance and tumor rejection has prompted extensive research into its structure and function. Understanding CD8α at the molecular level can lead to insights for improving immunotherapeutic strategies, particularly in cancer treatment and viral infections. Recombinant CD8α protein, produced using advanced biotechnology techniques, offers a valuable tool for studying its interactions with MHC I molecules and T cell receptors. Furthermore, this recombinant protein can be utilized in various applications, including vaccine development and as a potential target for monoclonal antibody therapy. Given the growing interest in harnessing the immune system to combat diseases, research on CD8α recombinant protein remains critical for advancing our knowledge of T cell biology and improving therapeutic outcomes in immunotherapy.
